Autores
Christophe Tournigand, Andres Cervantes, Arie Figer, Gérard Lledo, Michel Flesch, Marc Buyse, Laurent Mineur, Elisabeth Carola, Pierre-Luc Etienne, Fernando Rivera, Isabel Chirivella, Nathalie Perez-Staub, Christophe Louvet, Thierry André, Isabelle Tabah-Fisch, Aimery de Gramont
Fecha de publicación
2006/1/20
Revista
Journal of clinical oncology
Volumen
24
Número
3
Páginas
394-400
Editor
American Society of Clinical Oncology
Descripción
Purpose
In metastatic colorectal cancer, a combination of leucovorin (LV) and fluorouracil (FU) with oxaliplatin (FOLFOX) 4 is a standard first-line regimen. The cumulative neurotoxicity of oxaliplatin often requires therapy to be stopped in patients who are still responding. This study evaluates a new strategy of intermittent oxaliplatin treatment that is based on FOLFOX7, a simplified leucovorin and fluorouracil regimen with high-dose oxaliplatin.
Citas totales
Artículos de Google Académico
C Tournigand, A Cervantes, A Figer, G Lledo, M Flesch… - Journal of clinical oncology, 2006